Trend of A-share and Hong Kong stock innovative drug sector this week
In the second week of April 2022, a total of 9 stocks in the innovative drug sector in mainland and Hong Kong rose, 42 stocks fell, and the trading of cornerstone pharmaceutical-b was suspended. Among them, the top three gainers are Chuangsheng group-B (+ 23.49%), Shanghai Junshi Biosciences Co.Ltd(688180) -u (+ 9.95%), and Kaifa pharmaceutical-b (+ 7.21%). The top three declines were Rongchang bio-b (- 18.85%), Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) -u (- 14.79%), Corning Jerry pharmaceutical-b (- 12.51%). This week, the A-share innovative medicine sector fell 0.42%, outperforming the Shanghai and Shenzhen 300 index by 0.57pp, and biomedicine fell 2.63%. In the past six months, A-share innovative drugs fell by 17.7%, underperforming the CSI 300 index by 4.65pp, and biomedicine fell by 16.68%. This week, the innovative drug sector of Hong Kong stocks fell 3.75%, underperforming the Hang Seng Index by 2.13pp, and Hang Seng healthcare fell by 2.45%. In the past six months, innovative drugs in Hong Kong stocks fell by 21.59%, underperforming the Hang Seng Index by 7.97pp, and Hang Seng healthcare fell by 25.4%.
Progress of key innovative drugs in China
In April, a total of six new drugs were approved for marketing in China. This week, four drugs were approved for listing in China, and five innovative drugs were approved for new indications. The nmpa approved Pfizer’s abuxitinib tablets for the treatment of patients with moderate to severe atopic dermatitis. Nmpa approved bayerag’s larotinib capsule for the treatment of solid tumor patients carrying neurotrophic tyrosine receptor kinase fusion gene. TMPA approved Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) tigolasheng tablets for reflux esophagitis. Nmpa approved beclomethasone propionate + formoterol fumarate + gronbromide of Casey medicine for adult patients with moderate to severe chronic obstructive pulmonary disease.
Progress of overseas key innovative drugs
In April, four new drugs were approved by FDA and two new drugs were approved this week, namely dexmedetomidine and bendamustinehydrochloride. In April, no new drugs were approved for marketing in Europe. In April, no new drugs were approved for marketing in Japan.
This week’s small topic – research and development progress of CTLA4 target
There are 78 CTLA4 targets under research in the world. There are 45 monoclonal antibody projects, 14 double antibody projects, 9 CTLA4 Fc fusion protein projects and 3 car-t projects, including 3 approved for listing, 5 in phase III clinical, 7 in phase II clinical, 7 in phase I / II clinical and 28 in phase I clinical. China is studying 36. There are 25 monoclonal antibody projects, 7 double antibody projects and 4 CTLA4 Fc fusion protein projects, including 1 approved for marketing, 2 in phase III, 3 in phase II, 1 in phase I / II and 12 in phase I.
Progress of global key innovative drug transactions this week
This week, there were 11 key transactions in the world, and there were 4 key transactions with disclosed amount. Actinium pharmaceuticals and instant, telixpharmaceuticals and Eli Lilly, lenztheratics and Jixing, autigen and boehringeringelheim are involved.
Risk warning: drug price reduction risk; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
